BEGIN:VCALENDAR VERSION:2.0 PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:The BioCalendar X-ORIGINAL-URL:https://thebiocalendar.com X-WR-CALDESC:Events for The BioCalendar REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20270314T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20271107T090000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20260308T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20261101T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20270314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20271107T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T160000 DTEND;TZID=America/Los_Angeles:20260520T183000 DTSTAMP:20260613T080742 CREATED:20260415T163842Z LAST-MODIFIED:20260415T163842Z UID:10202-1779292800-1779301800@thebiocalendar.com SUMMARY:BVS' Biotech Community Event at Biovista\, San Diego DESCRIPTION:We are very excited to announce our outdoor Biotech Community Event at the Biovista Life Science Campus. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \n✨ What to Expect: \n Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n Delicious Appetizers by California English & Drinks: Enjoy delicious appetizers as you network and explore the vendor exhibits. \nWe are inviting all the tenants and all local life science researchers and entrepreneurs in the surrounding area to attend. \nAdmission Details:\nFREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes.\n$200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/bvs-biotech-community-event-at-biovista-san-diego-3/ ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-05-20-26.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T130000 DTEND;TZID=America/Los_Angeles:20260520T140000 DTSTAMP:20260613T080742 CREATED:20260429T125734Z LAST-MODIFIED:20260429T125734Z UID:10300-1779282000-1779285600@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Large Molecule DESCRIPTION:Watch Leading CDMOs share their current capabilities\, facility locations\, and timelines – to help you identify options for your development and manufacturing needs. \nDive into the biopharmaceutical realm\, where the synthesis of biologically derived APIs encompasses cell line development\, fermentation\, and sophisticated purification techniques. The event will feature insights into process optimization and scale-up\, which are crucial for meeting production demands without compromising quality. Discover the meticulous quality control practices that underpin the production of biopharmaceuticals\, laying the groundwork for novel biologic therapies. \nWhat can you expect? – Short\, digital presentations to give you an inside look at the current capabilities of industry suppliers. You will have the opportunity to submit questions of each CDMO to better understand if they can meet your needs – all from the convenience of your computer! URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-large-molecule/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-19.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T130000 DTEND;TZID=America/Los_Angeles:20260520T140000 DTSTAMP:20260613T080742 CREATED:20260421T103753Z LAST-MODIFIED:20260421T103753Z UID:10233-1779282000-1779285600@thebiocalendar.com SUMMARY:Cleanroom ISO Classification: The Framework for Containment in a Cleanroom DESCRIPTION:Cleanroom ISO classification is a foundational decision that directly impacts facility design\, GMP manufacturing operations\, and regulatory outcomes in biotech and pharmaceutical environments. This is especially critical in cell and gene therapy\, viral vector\, API\, mRNA\, and sterile ATMP manufacturing\, where product protection\, biohazard containment\, and operator safety must be carefully balanced. \nIn this webinar\, we’ll explore how ISO classification strategy shapes key aspects of cleanroom design\, including process layout\, HVAC system design\, air change rates\, pressurization schemes\, and airlock sequencing in Biosafety Level and OEB-driven environments. \nAttendees will learn why early alignment between process operations\, containment strategy\, and regulatory expectations is essential when working with biohazardous materials\, high-potency compounds\, and patient-specific therapies. Without this alignment\, organizations risk costly redesigns\, operational inefficiencies\, and compliance challenges. \nWe’ll also examine how misaligned classification decisions can limit manufacturing flexibility\, increase operator exposure risk\, and weaken containment strategies. \nDrawing on real-world project experience across viral vector and cell processing facilities\, this session will demonstrate how integrating ISO classification into early design phases supports effective containment\, cross-contamination control\, and inspection readiness. The webinar will emphasize practical approaches to aligning cleanroom infrastructure with process needs to help you build safe\, compliant\, and scalable ATMP manufacturing operations that meet both current and future goals. \nKey Learning Objectives:\n– Understand how ISO classification drives cleanroom containment\, HVAC system approach\, pressurization strategies\, airlock scheme\, and GMP manufacturing quality\n – Identify compliance\, cross-contamination and operational risks caused by misaligned ISO classification strategies in ATMP manufacturing cleanrooms\n – Recognize the relationship between process operations\, contamination risk\, and ISO classification selection through early planning to support inspection readiness URL:https://thebiocalendar.com/event/cleanroom-iso-classification-the-framework-for-containment-in-a-cleanroom/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-20-26-AES-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260520T110000 DTEND;TZID=America/New_York:20260520T133000 DTSTAMP:20260613T080742 CREATED:20260430T151538Z LAST-MODIFIED:20260430T151538Z UID:10308-1779274800-1779283800@thebiocalendar.com SUMMARY:BVS' Showcase in Partnership with Related Beal-Seaport District\, Boston DESCRIPTION:BVS in partnership with Related Beal\, LLC inviting you to our Biotech Community Event in the heart of Boston’s Seaport district. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nWe are inviting all research scientists from the institutes\, biotech/pharma\, and other companies in the Seaport district and surrounding areas to attend this event. \n✨ What to Expect: \n Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n Delicious Food & Drinks: Enjoy delicious refreshments as you network and explore the vendor exhibits. \nAdmission Details: \n FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes.\n $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/bvs-showcase-in-partnership-with-related-beal-seaport-district-boston/ ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-05-20-26-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T110000 DTEND;TZID=America/Los_Angeles:20260520T120000 DTSTAMP:20260613T080742 CREATED:20260501T144546Z LAST-MODIFIED:20260501T144546Z UID:10323-1779274800-1779278400@thebiocalendar.com SUMMARY:Modernizing Mouse Colony Management: Where the 3Rs and Performance Meet DESCRIPTION:What if advancing the 3Rs also improved your timelines\, budgets\, and scientific outcomes? \nThis webinar challenges the perceived tradeoff between the 3Rs and operational performance in colony management. We will explore how a thoughtful combination of IVF\, cryopreservation\, electroporation\, genotyping\, and digital colony management can reduce animal use\, stabilize genetic backgrounds\, and simplify day to day rodent breeding management. \nBy reviewing practical examples\, case studies\, and quantitative data\, you’ll learn how to: \n\nAlign 3Rs principles with faster timelines and better cost efficiency\nUse modern technologies to simplify and stabilize colony management\nImprove research reproducibility through enhanced genetic and colony control\n\nThis webinar is designed for members of in vivo research teams and colony management leaders seeking to reduce animal use while improving efficiency and reproducibility. URL:https://thebiocalendar.com/event/modernizing-mouse-colony-management-where-the-3rs-and-performance-meet/ LOCATION:Online webinar CATEGORIES:Webinar END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T110000 DTEND;TZID=America/Los_Angeles:20260520T120000 DTSTAMP:20260613T080742 CREATED:20260429T125556Z LAST-MODIFIED:20260429T125556Z UID:10296-1779274800-1779278400@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Combination Products & Drug Delivery DESCRIPTION:The move toward self-administered\, home-based treatments has made drug–device combination products a strategic priority. Success now requires tight integration across formulation\, device design\, testing\, human factors\, and regulatory strategy—not separate workflows. \nThis session outlines the key decisions and capabilities for successful programs\, including choosing platform vs. custom devices\, ensuring formulation–device compatibility\, and meeting testing standards. It also covers regulatory expectations\, human factors validation\, and scaling manufacturing for autoinjectors and wearables—plus how early planning and emerging digital strategies can reduce risk and accelerate development. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-combination-products-drug-delivery/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-18.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260519T130000 DTEND;TZID=America/Los_Angeles:20260519T140000 DTSTAMP:20260613T080742 CREATED:20260429T125254Z LAST-MODIFIED:20260429T125254Z UID:10292-1779195600-1779199200@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Highly Potent Drug Development & Manufacturing DESCRIPTION:This event brings together pharmaceutical and biotech professionals\, CDMOs\, and technology providers to discuss the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs). This event shares presentations focused on key topics such as containment technologies\, process scale-up\, regulatory compliance\, and occupational safety in HPAPI manufacturing. The event also serves as a networking platform where CDMOs showcase their capabilities—such as specialized facilities\, containment systems\, and expertise in handling highly toxic compounds—allowing pharma and biopharma companies to evaluate potential outsourcing and development partners. \nPurpose for attendees:\n– Enable CDMOs to present their technical capabilities and facilities for handling potent compounds\n– Facilitate partnership discussions and outsourcing opportunities in drug development and manufacturing URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-highly-potent-drug-development-manufacturing/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-17.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260519T110000 DTEND;TZID=America/Los_Angeles:20260519T120000 DTSTAMP:20260613T080742 CREATED:20260429T125014Z LAST-MODIFIED:20260429T125014Z UID:10288-1779188400-1779192000@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Mammalian Cell Culture DESCRIPTION:This online event brings together pharmaceutical and biotechnology companies with contract development and manufacturing organizations (CDMOs) specializing in mammalian cell culture–based biologics production. Through a series of concise presentations\, participating CDMOs showcase their capabilities across the biologics development lifecycle\, including cell line development\, upstream and downstream process development\, scale-up\, and GMP manufacturing. \nThe event is designed to help drug developers evaluate potential outsourcing partners by highlighting available capacity\, technical platforms\, facility infrastructure\, and expertise in producing complex biologics such as monoclonal antibodies and recombinant proteins. Attendees gain practical insights into manufacturing strategies\, timelines\, and partnership models while having the opportunity to engage directly with CDMO experts to determine the best fit for their development and commercialization needs. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-mammalian-cell-culture/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-16.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260519T110000 DTEND;TZID=America/Los_Angeles:20260519T120000 DTSTAMP:20260613T080742 CREATED:20260422T125020Z LAST-MODIFIED:20260422T125020Z UID:10245-1779188400-1779192000@thebiocalendar.com SUMMARY:From Protocol to Patient Risk: How to Build Safer\, Faster Trials by Integrating Clinical Operations and Pharmacovigilance Early DESCRIPTION:Clinical execution and pharmacovigilance are often managed in parallel rather than in partnership. For sponsors\, that disconnect can create avoidable delays\, inconsistent safety decision-making\, protocol amendments\, and added pressure on sites and study teams. In early-phase and complex trials\, where risk profiles are still emerging\, these gaps can have a direct impact on both patient safety and development timelines. \nJoin experts from Ergomed Clinical Research and PrimeVigilance for a practical discussion on how earlier integration across clinical operations\, medical monitoring\, and pharmacovigilance can strengthen study oversight from the outset. This webinar will examine where silos tend to emerge\, how integrated planning can reduce downstream issues\, and what sponsors can do to build a more connected model across protocol strategy\, trial conduct\, individual case safety report handling\, and signal and risk management. \nAttendees will gain practical insight into how a more aligned clinical and safety strategy can support better benefit-risk decisions\, reduce operational risk\, and help keep complex studies on track. \nKey Takeaways:\n– Why separating clinical operations and safety oversight creates avoidable risk in clinical development\n– Where silos most often create issues\, including delayed decisions\, protocol amendments\, inconsistent safety data handling incl. signal and risk management\, and added site burden\n– What integrated planning and execution looks like in practice across study design\, medical monitoring\, pharmacovigilance\, and trial conduct\n– How earlier collaboration can support stronger decision-making\, operational readiness\, and timeline protection\n– Practical ways to reduce downstream risk while improving both patient safety and study efficiency URL:https://thebiocalendar.com/event/from-protocol-to-patient-risk-how-to-build-safer-faster-trials-by-integrating-clinical-operations-and-pharmacovigilance-early/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-19-26-Ergomed-eblast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260515T200000 DTEND;TZID=America/Los_Angeles:20260515T233000 DTSTAMP:20260613T080742 CREATED:20260424T160017Z LAST-MODIFIED:20260424T160017Z UID:10253-1778875200-1778887800@thebiocalendar.com SUMMARY:Concert for Cures: P!NK DESCRIPTION:This year\, Curebound is proud to welcome one of the world’s most celebrated and beloved artists: P!NK \nTickets on sale now!  \nSince bursting onto the scene in 2000\, P!NK has built a career defined by fearless honesty\, unforgettable live shows\, and a refusal to fit a mold. Across nine studio albums and a greatest hits collection\, she’s sold over 60 million albums worldwide\, earned 15 Top 10 hits on the Billboard Hot 100 (including four #1s)\, and packed-out arenas and stadiums across the globe with her high-energy\, high-flying performances. \nHer work has been recognized with three Grammy Awards (and 21 nominations) and she was named Billboard Music Awards’ Icon in 2021 and iHeartRadio’s Icon in 2023. A trailblazer and passionate advocate for the causes she holds dear\, P!NK continues to evolve — staying true to herself and inspiring millions to do the same. \nThe event is recognized for bringing together community energy to fund research that changes how cancer is detected\, treated\, and survived. Tickets and information for the 2026 event are available at Curebound.org. URL:https://thebiocalendar.com/event/concert-for-cures-pnk/ LOCATION:San Diego\, San Diego\, CA\, United States CATEGORIES:Fundraiser,Social END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T170000 DTEND;TZID=America/Los_Angeles:20260514T190000 DTSTAMP:20260613T080742 CREATED:20260504T223230Z LAST-MODIFIED:20260504T223230Z UID:10344-1778778000-1778785200@thebiocalendar.com SUMMARY:Launching the Future of Leadership in Our Community DESCRIPTION:LiB Bay Area Regional Ambassador Pilot kicks off May 14 at Genentech\, connecting life sciences professionals & local members. \n\n\n\n\nJoin Latinos in Bio for the Bay Area kickoff of our Regional Ambassador Pilot\, an initiative to grow our West Coast presence and connect Latinx life sciences professionals. \nThis special evening\, hosted in partnership with Genentech\, will combine casual networking with a brief introduction to LiB. Meet LiB leadership\, connect with fellow members\, and learn how the Regional Ambassador Pilot will foster a thriving Bay Area community. URL:https://thebiocalendar.com/event/launching-the-future-of-leadership-in-our-community/ LOCATION:South San Francisco\, CA\, CA\, 94080\, United States CATEGORIES:Networking END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260613T080742 CREATED:20260429T123929Z LAST-MODIFIED:20260429T123929Z UID:10284-1778756400-1778760000@thebiocalendar.com SUMMARY:Strategic Early Material Generation for Accelerated Process Development DESCRIPTION:Rapid access to early-stage material is critical for biologics development\, especially as molecular complexity increases and timelines expand. Generating scalable\, high-quality material early helps streamline developability assessments and process development. \nIn this webinar\, Samsung Biologics presents its strategy for early material generation\, integrating it with cell line development (CLD)\, early optimization\, and stable expression platforms. This approach delivers consistent\, production-relevant material—nearly equivalent to single-clone sources—while reducing variability\, time\, and complexity. \nLearn how this streamlined workflow accelerates development from sequence to material\, supports downstream activities\, and improves efficiency. Case studies will highlight scalable production from flask to bioreactor and the impact of early decisions on timelines and costs. \nKey benefits:\n– Faster\, more efficient early-stage biologics development\n– Improved scalability through alignment with CLD\n– Reliable material supply for process and formulation studies URL:https://thebiocalendar.com/event/strategic-early-material-generation-for-accelerated-process-development-2/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Samsung-eblast-700x200-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260613T080742 CREATED:20260429T123708Z LAST-MODIFIED:20260429T123708Z UID:10280-1778756400-1778760000@thebiocalendar.com SUMMARY:Understanding the Regulatory Landscape for Ophthalmic Drug Products: Contamination Control Strategies\, USP \, and Purpose-Built Solutions DESCRIPTION:Ophthalmic drugs face strict regulations\, including USP limits on particulate matter and updated EU GMP Annex 1 requirements for comprehensive Contamination Control Strategies (CCS). These standards emphasize minimizing contamination across packaging\, sterilization\, and system controls. \nThis webinar explores how these regulations impact real-world development challenges and how purpose-built packaging—featuring low particulates\, silicone-free designs\, and advanced barrier technologies—can support compliance\, improve dose accuracy\, and reduce risk. \nYou’ll learn:\n– The role of CCS in reducing contamination risks\n– Key regulatory requirements\, including USP\n– Common challenges like particulates\, silicone oil\, and endotoxins\n– Packaging solutions for safer ophthalmic drug delivery \nKey takeaways:\n– Build an effective CCS\n– Understand ophthalmic vs. injectable requirements\n– Interpret USP limits\n– Evaluate solutions for compliant drug delivery URL:https://thebiocalendar.com/event/understanding-the-regulatory-landscape-for-ophthalmic-drug-products-contamination-control-strategies-usp-and-purpose-built-solutions-2/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-West-eBlast-700x200-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260613T080742 CREATED:20260416T190955Z LAST-MODIFIED:20260416T190955Z UID:10214-1778756400-1778760000@thebiocalendar.com SUMMARY:Strategic Early Material Generation for Accelerated Process Development DESCRIPTION:Accelerate biologics development by enabling rapid access to scalable\, production-relevant early-stage material that supports developability assessment and process optimization. This webinar highlights Samsung Biologics’ integrated approach\, aligning material generation with cell line development\, incorporating early optimization\, and leveraging stable expression platforms to deliver consistent\, high-quality material with reduced variability. Learn how this streamlined strategy shortens timelines\, simplifies processes\, and improves resource efficiency\, supported by case studies demonstrating successful scale-up from flask to bioreactor. \nKey Takeaways:\n– The role of early material generation in enabling efficient biologics development and early developability assessment\n– How aligning material generation with cell line development supports both speed and scalability from early stages\n– How scalable\, production-relevant material supports process development activities\, including formulation studies and other material-intensive applications\, while improving overall time and resource efficiency URL:https://thebiocalendar.com/event/strategic-early-material-generation-for-accelerated-process-development/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Samsung-eblast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260613T080742 CREATED:20260409T125450Z LAST-MODIFIED:20260409T125450Z UID:10176-1778756400-1778760000@thebiocalendar.com SUMMARY:AI Meets Informed Consent: Opportunity\, Risk\, and What IRBs Need to See DESCRIPTION:The informed consent process is an ongoing dialogue that helps participants decide\, with full understanding\, whether to take part in a clinical trial. As generative AI begins to influence how consent documents are created\, translated\, and delivered\, this process is becoming more complex. \nJoin experts in IRB oversight\, research ethics\, and health literacy to explore the opportunities and challenges of AI-assisted informed consent. This session will cover ethical foundations\, emerging use cases for generative AI\, and what sponsors and CROs need to communicate to IRBs when using these tools. \nDesigned for clinical operations leaders across biopharma\, medtech\, and CROs\, this discussion will provide a practical framework for evaluating AI-driven consent approaches while keeping patient understanding and protection at the center. URL:https://thebiocalendar.com/event/ai-meets-informed-consent-opportunity-risk-and-what-irbs-need-to-see/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Brany-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260512T130000 DTEND;TZID=America/Los_Angeles:20260512T140000 DTSTAMP:20260613T080742 CREATED:20260413T161457Z LAST-MODIFIED:20260413T161458Z UID:10190-1778590800-1778594400@thebiocalendar.com SUMMARY:Don’t Sacrifice Compliance: Strategies for Audit-Ready System Integrations DESCRIPTION:Discover how modern integration strategies are enabling companies to bridge critical systems\, streamline data flow\, and maintain regulatory confidence that supports innovation and compliance\, so your systems evolve as fast as your business. URL:https://thebiocalendar.com/event/dont-sacrifice-compliance-strategies-for-audit-ready-system-integrations/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-12-26-Blue-Mountain-Reg-1920x250-rev.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260512T110000 DTEND;TZID=America/Los_Angeles:20260512T120000 DTSTAMP:20260613T080742 CREATED:20260417T125535Z LAST-MODIFIED:20260417T125535Z UID:10222-1778583600-1778587200@thebiocalendar.com SUMMARY:Distributed Manufacturing for CGT: Rent\, Lease\, or Buy in an Era of Overcapacity? DESCRIPTION:As cell and gene therapy companies navigate the 2026 landscape marked by manufacturing overcapacity\, a strategic question is no longer if to outsource\, but how. \nFor leaders across MSAT\, CMC\, and technical operations\, the choice between renting\, leasing\, or building distributed manufacturing capabilities has direct implications for speed to clinic\, capital efficiency\, and long-term scalability. Critically\, many organizations still face a persistent gap in generating high-quality IND-enabling material early\, an issue that can delay clinical entry and jeopardize key funding milestones. \nIn this Cell & Gene Live\, Chief Editor Erin Harris will be joined by Sugu Patro\, Ph.D.\, SVP Global Process Development\, at Kite Pharma and Emily Moran\, Founder and Principal of 3LB Consulting\, who will unpack what biotech teams should prioritize when evaluating partners in an overcapacity market\, how to align early manufacturing strategy with clinical and financial goals. They will also share lessons to be drawn from Kite’s in-house expertise to build more resilient\, future-ready manufacturing models. URL:https://thebiocalendar.com/event/distributed-manufacturing-for-cgt-rent-lease-or-buy-in-an-era-of-overcapacity/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/26_05_CGL_LinkedIn_1280x720.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260512T110000 DTEND;TZID=America/Los_Angeles:20260512T120000 DTSTAMP:20260613T080742 CREATED:20260414T133825Z LAST-MODIFIED:20260414T133825Z UID:10194-1778583600-1778587200@thebiocalendar.com SUMMARY:Applying AI to Study Simulation: From Design to Analysis DESCRIPTION:AI is making it possible to simulate clinical trials before they begin using realistic synthetic patient cohorts built from real-world data. \nIn this session\, you’ll see how these simulations compare to actual Phase 2 and Phase 3 trial data\, and how teams are using them to test protocols\, reduce risk\, and improve study design faster. \nWe’ll also explore how TrialKit brings these capabilities into a single platform for simulation\, analysis\, and execution. \nYou’ll learn:\n– How synthetic patient cohorts are created and validated\n– How to simulate and refine trials before enrolling patients\n– Key considerations for applying AI in clinical research URL:https://thebiocalendar.com/event/applying-ai-to-study-simulation-from-design-to-analysis/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-12-26-Crucial-Data-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260512T080000 DTEND;TZID=America/Los_Angeles:20260512T103000 DTSTAMP:20260613T080742 CREATED:20260504T223323Z LAST-MODIFIED:20260504T223323Z UID:10345-1778572800-1778581800@thebiocalendar.com SUMMARY:Bay Area Biotech Forum DESCRIPTION:From research to regulation\, the biotech industry is taking a hit\, but drug-development companies continue to press forward\, moving important discoveries from the lab bench to the patient bedside. \nThe program will begin with a talk with Ultragenyx CEO Emil Kakkis\, the scientist behind the first treatment for an ultra-rare genetic disease\, and Ryan Dant\, the first patient. Moderated by Ron Leuty. \nOur panel will explore the macro issues and micro decisions shaping the Bay Area biotech ecosystem\, along with the opportunities ahead. URL:https://thebiocalendar.com/event/bay-area-biotech-forum-2/ LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States CATEGORIES:Forum END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260512 DTEND;VALUE=DATE:20260515 DTSTAMP:20260613T080742 CREATED:20260330T202508Z LAST-MODIFIED:20260330T202508Z UID:10116-1778544000-1778803199@thebiocalendar.com SUMMARY:Fierce Biotech Week DESCRIPTION:Be in the Room Where Decisions Are Made \n\n\n\n\n\n\n\n\nFierce Biotech Week attracts senior leaders across biotech and pharma\, including: \n\n\nC-suite executives and founders \n\n\nHeads of R&D and Drug Development \n\n\nClinical & TMF leadership \n\n\nBD&L and corporate strategy teams \n\n\nPR & Communications executives \n\n\nStrategic outsourcing partners \n\n\nThis is not a spectator audience. It’s a room of decision-makers. URL:https://thebiocalendar.com/event/fierce-biotech-week-2/ LOCATION:Boston\, MA\, 02210\, United States CATEGORIES:Summit END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260511T110000 DTEND;TZID=America/Los_Angeles:20260511T120000 DTSTAMP:20260613T080742 CREATED:20260429T123417Z LAST-MODIFIED:20260429T123417Z UID:10276-1778497200-1778500800@thebiocalendar.com SUMMARY:ADC Outsourcing: Plan Smart Now or Suffer Later DESCRIPTION:Antibody-drug conjugates (ADCs) bring together multiple scientific and operational disciplines\, which makes early and ongoing outsourcing decisions especially consequential. This event examines how sponsors think through outsourcing strategies across discovery support\, process development\, bioconjugation\, analytical work\, drug substance\, and fill-finish\, focusing on what should remain internal and what should be outsourced to external partners. Our panel will discuss how to evaluate capabilities\, sequence development activities\, avoid fragmentation across vendors\, and build an outsourcing plan that supports speed without creating unnecessary technical or program risk. URL:https://thebiocalendar.com/event/adc-outsourcing-plan-smart-now-or-suffer-later/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-15.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260511T110000 DTEND;TZID=America/Los_Angeles:20260511T120000 DTSTAMP:20260613T080742 CREATED:20260410T130948Z LAST-MODIFIED:20260410T130948Z UID:10185-1778497200-1778500800@thebiocalendar.com SUMMARY:Design scalable downstream processes with practical purification and analytical strategies DESCRIPTION:Downstream process development is rapidly evolving as new modalities\, from mAbs to mRNA\, viral vectors\, and other complex molecules\, enter development pipelines. This webinar will share practical strategies and analytical considerations for designing robust\, scalable purification processes across diverse molecule types. \nDrawing on decades of chromatography innovation and the expertise of our global Fast Trak™ process development (PD) teams\, Cytiva speakers will show how we use tools such as our Biacore™ surface plasmon resonance (SPR) system and size-exclusion chromatography with multi-angle light scattering (SEC-MALS) to clarify complex mechanisms\, address unpredictable impurities\, and overcome challenges that traditional approaches cannot resolve. \nYou will also hear how the combination of this experience\, advanced analytics\, and focused knowledge transfer can accelerate development\, reduce risk\, and help customers build lasting internal capability and true process ownership. \nUsing case examples spanning proteins\, antibodies\, nucleic acids\, viruses\, and vesicles\, we will feature common downstream pitfalls and highlight how our integrated chromatography and analytical strengths help avoid them. Whether you are advancing proof of concept or preparing to scale up\, you will leave with a clear view of how Cytiva PD\, SPR\, and chromatography leadership enables efficient\, confident downstream development—even for the most complex modalities. \nKey Learning Objectives: \n Learn practical\, scalable approaches for developing chromatography‑based purification processes\n Understand how advanced analytical tools such as SPR (Biacore™ system) and SEC‑MALS reveal complex molecular interactions and impurity mechanisms\n Explore how combining chromatography expertise\, advanced analytics\, and structured knowledge transfer accelerates development and builds long‑term process capability URL:https://thebiocalendar.com/event/design-scalable-downstream-processes-with-practical-purification-and-analytical-strategies/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-11-26-Cytiva-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260511T080000 DTEND;TZID=America/Los_Angeles:20260514T170000 DTSTAMP:20260613T080742 CREATED:20251206T100827Z LAST-MODIFIED:20251206T100827Z UID:9622-1778486400-1778778000@thebiocalendar.com SUMMARY:AAPS National Biotechnology Conference DESCRIPTION:The AAPS National Biotechnology Conference (NBC) is a premier annual event by the American Association of Pharmaceutical Scientists (AAPS) for leaders in pharma and biotech to explore cutting-edge science in biologics\, advanced therapies\, and innovative drug development\, focusing on new modalities like CAR-T\, gene therapies\, and AI in drug discovery\, bridging research from lab to patient. It features scientific sessions\, poster presentations\, and networking opportunities\, addressing challenges in formulation\, bioanalysis\, manufacturing\, and translational science for complex drugs URL:https://thebiocalendar.com/event/aaps-national-biotechnology-conference/ LOCATION:San Diego\, San Diego\, CA\, United States CATEGORIES:Academic Research,Summit,Symposium END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260511 DTEND;VALUE=DATE:20260516 DTSTAMP:20260613T080742 CREATED:20251206T101440Z LAST-MODIFIED:20260116T121409Z UID:9625-1778457600-1778889599@thebiocalendar.com SUMMARY:PEGS Boston DESCRIPTION:The PEGS Boston Summit is where the future of biologics takes shape. For over 20 years\, PEGS is the go-to event for protein and antibody engineering\, drug development\, immunotherapy\, radiotherapy\, and AI/ML-driven biologics research. New in 2026: a dedicated focus on peptides\, spotlighting their therapeutic power\, design innovations\, and expanding role in drug discovery. \nWith 350+ presentations\, breakout sessions\, and interactive training seminars\, PEGS delivers the insights and connections you need to stay ahead. The exhibit hall buzzes with top technology and service providers\, giving you a front-row seat to the tools transforming the industry. \nDon’t just follow the science – be part of it. Join us at the 2026 PEGS Boston Summit and connect with the leaders shaping what’s next in biologics and beyond. URL:https://thebiocalendar.com/event/pegs-boston-3/ LOCATION:Boston\, MA\, 02210\, United States CATEGORIES:Featured,Summit ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/12/pegs2026-scaled.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260511 DTEND;VALUE=DATE:20260516 DTSTAMP:20260613T080742 CREATED:20251206T101044Z LAST-MODIFIED:20251206T101044Z UID:9623-1778457600-1778889599@thebiocalendar.com SUMMARY:ASGCT Annual Meeting DESCRIPTION:The ASGCT Annual Meeting is the leading global event for professionals in gene and cell therapy\, hosted by the American Society of Gene + Cell Therapy (ASGCT) to showcase cutting-edge research\, new technologies\, and clinical applications\, offering crucial networking for scientists\, industry leaders\, and clinicians to advance treatments for human diseases. It features expert presentations\, novel abstract presentations\, workshops\, and exhibitions from companies in the cell and gene therapy ecosystem. URL:https://thebiocalendar.com/event/asgct-annual-meeting/ LOCATION:Boston\, MA\, 02210\, United States CATEGORIES:Academic Research,Networking,Presentation END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260508T110000 DTEND;TZID=America/Los_Angeles:20260508T120000 DTSTAMP:20260613T080742 CREATED:20260408T173023Z LAST-MODIFIED:20260408T173023Z UID:10168-1778238000-1778241600@thebiocalendar.com SUMMARY:From Insights to Impact: Predictive Models and PAT for More Efficient and Robust Biologics Manufacturing DESCRIPTION:Explore how data-driven tools and Process Analytical Technology (PAT) can optimize scale-up\, enhance process control\, and reduce risk from cell culture through drug product. Learn how integrating advanced modeling and real-time monitoring enables more reliable\, cost-effective\, and scalable biologics production. \nKey takeaways include:\n– Applying predictive\, engineering-driven models to improve bioreactor scale-up and performance\n– Using mechanistic models and data to enable robust tech transfer and process optimization\n– Leveraging PAT tools for real-time monitoring\, adaptive control\, and process stability\n– Scaling lyophilization with design space approaches to ensure product quality and consistency\n– Reducing scale-up uncertainty and accelerating path to commercial manufacturing URL:https://thebiocalendar.com/event/from-insights-to-impact-predictive-models-and-pat-for-more-efficient-and-robust-biologics-manufacturing/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-08-26-Lonza-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260508 DTEND;VALUE=DATE:20260510 DTSTAMP:20260613T080742 CREATED:20260507T184645Z LAST-MODIFIED:20260507T184645Z UID:10402-1778198400-1778371199@thebiocalendar.com SUMMARY:2026 @Philly Cell and Gene Therapy Annual Conference DESCRIPTION:This meeting brings together the innovators and business leaders to foster collaborations and advance CGT in the Greater Philadelphia area. URL:https://thebiocalendar.com/event/2026-philly-cell-and-gene-therapy-annual-conference/ LOCATION:King of Prussia\, PA\, King of Prussia\, PA\, 19406\, United States CATEGORIES:Presentation,Summit END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260507T163000 DTEND;TZID=America/New_York:20260507T190000 DTSTAMP:20260613T080742 CREATED:20260415T164149Z LAST-MODIFIED:20260415T164149Z UID:10206-1778171400-1778180400@thebiocalendar.com SUMMARY:JLL & BVS’ Spring Community Celebration in Tarrytown\, New York DESCRIPTION:BVS in collaboration with JJL is excited to host our first indoor JLL & BVS’ Spring Community Celebration in Tarrytown. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nWe invite all entrepreneurs\, researchers\, and scientists from institutes\, biotech firms\, and other companies in Tarrytown and the surrounding areas to join us for this event. This gathering brings together professionals from the healthcare\, biotech\, academic\, and local business communities for networking\, collaboration\, and knowledge sharing. \n✨ What to Expect: \n Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n Lab Tours: Take a tour of the lab space available at 500 White Plains Road\n Delicious Appetizers & Drinks: Enjoy delicious spring-inspired appetizers\, craft beer\, wine and the “Westchester Spring Spritz” Prosecco cocktail\, as you network and explore the vendor exhibits. \nAdmission Details: \n FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes.\n $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/jll-bvs-spring-community-celebration-in-tarrytown-new-york-2/ ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-05-7-26-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260507T130000 DTEND;TZID=America/Los_Angeles:20260507T140000 DTSTAMP:20260613T080742 CREATED:20260402T160919Z LAST-MODIFIED:20260402T160920Z UID:10129-1778158800-1778162400@thebiocalendar.com SUMMARY:How to Activate Industrial AI Under GxP\, Governance\, and Security Constraints DESCRIPTION:This webinar invites an interactive dialogue to explore how Industrial AI can be introduced where plants are today. We’ll walk through what is real and working now to turn insights into governed\, auditable actions\, with human oversight by design. URL:https://thebiocalendar.com/event/how-to-activate-industrial-ai-under-gxp-governance-and-security-constraints/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-07-26-Siemens-Reg-Banner-1920x250-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260507T110000 DTEND;TZID=America/Los_Angeles:20260507T120000 DTSTAMP:20260613T080742 CREATED:20260408T172649Z LAST-MODIFIED:20260408T172653Z UID:10162-1778151600-1778155200@thebiocalendar.com SUMMARY:Early Developability Assessment for Antibody Based Therapeutics DESCRIPTION:Discover how integrated in silico and in vitro approaches can assess developability\, manufacturability\, and immunosafety at the earliest stages. Learn how a toolbox strategy enables smarter candidate selection\, reduces downstream risk\, and supports faster progression of multi-specific antibodies into clinical development. \nKey takeaways include:\n– Early identification of developability and immunosafety risks in multi-specific antibodies\n– How combined in silico and in vitro screening improves lead selection\n– Strategies to enhance manufacturability and product quality from the start\n– Using a toolbox approach to streamline development and accelerate timelines URL:https://thebiocalendar.com/event/early-developability-assessment-for-antibody-based-therapeutics/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-07-26-Lonza-eBlast-700x200-2.png END:VEVENT END:VCALENDAR